8 responses to “Moving into the treatment phase of the COVID-19 pandemic”

  1. Great summary. Thank you.

  2. Excellent resource. Thank you.

  3. You do not appear to be considering Long COVID in this article. I am curious what your approach is to monitoring for Long COVID with your patients after their COVID infection and how you are treating this.

  4. Thank you for this helpful summary with many practical suggestions for a rational and patient-centred approach.

    Thank you also to the TCMP team and authors for being transparent with disclosures, featuring them prominently at the top of the article! The level of detail and mitigating efforts are useful to know about when considering the content of the article.

    Perhaps, more relevant for articles other than this, I always keep in mind that disclosures don’t render a conflict of interest (COI) acceptable, but create transparency which promotes consideration of what is and is not acceptable. Surprisingly, simple disclosure can have the opposite of the intended or expected effect – (see https://www.nytimes.com/2016/07/10/opinion/sunday/the-paradox-of-disclosure.html / Sah S, Fagerlin A, Ubel P. Effect of physician disclosure of specialty bias on patient trust and treatment choice. Proceedings of the National Academy of Sciences of the United States of America. 2016;113(27):7465-7469 for more) – so avoidance of COI is the ideal to strive for.

  5. Keeping up to date on who is at risk, when to consider treatment, and what to do is an ongoing challenge. Thanks for the update.

  6. Makes a lot of sense
    UBC has provided excellent webinars and is an excellent resource that I use and willuse the other on :BCSBC as well

  7. Any use of simple OTC meds such as Ceterizine plus Famotidine or a macride antibiotic plus Ceterizine? or a variety of other combinations or an inhaled steroid or Prednisone aimed at limiting inflammation?
    We have used this much less expensive approach in our charity work in India and here in BC.
    Theee combos are far less expensive and considerably lower side effects and drug interactions.

  8. Problems with paxlovid
    Study done on unvaccinated patients
    Number needed to treat 34
    Very many drug interactions

Leave a Reply